UnitedHealth Group Incorporated (UNH)
UnitedHealth: Expect A New Normal In CMS Funding - Maintain Buy
The market has over-reacted to UNH's cautious FY2025 guidance, since the lower bottom-line is attributed to "CMS payment cuts, the IRA, and a mismatch between Medicaid rates and medical program." Given the recently released Star rating for 2025, we believe that the redeterminations and higher medical costs may be a new normal across the health care provider industry. For now, UNH has attempted to optimize its operations while managing the Optum therapy/ drug costs, resulting in the segment's growing profit margins and decent FY2024 guidance.
UnitedHealth Group Pulls Back Into A Healthy Buying Opportunity
UnitedHealth Group's UNH stock price pulled back following the Q3 earnings release in what can best be described as a temper tantrum. The results weren't bad, outpacing the consensus estimates and compounded by solid guidance, but the market wanted more, so it sold off.
Elevance Health: Why Invest Over UnitedHealth Group?
Despite a disappointing Q3 report, Elevance Health remains attractive due to its relatively favorable valuation compared to UnitedHealth Group and a total shareholder yield of roughly 3.5%. Elevance's expansion into healthcare services through Carelon and continued strength in Medicare and Medicaid markets support long-term growth, especially given the industry's demographic tailwinds. Though 2024 is a “reset” year, Elevance management's outlook for 2025 and beyond points to strong potential margin recovery and continued earnings growth.
Should You Pick UNH Stock At $560?
UnitedHealth Group (NYSE: UNH) recently reported its Q3 results, with revenues and earnings exceeding our expectations. The company reported revenue of $100.8 billion and adjusted earnings of $7.15 per share, compared to our estimates of $99 billion and $6.95, respectively.
UnitedHealth Group Pulls Back Into a Healthy Buying Opportunity
UnitedHealth Group's NYSE: UNH stock price pulled back following the Q3 earnings release in what can best be described as a temper tantrum. The results weren't bad, outpacing the consensus estimates and compounded by solid guidance, but the market wanted more, so it sold off.
Why 5 Of 6 UnitedHealth Analysts Are Cutting Forecasts After Q3 Earnings Release
UnitedHealth Group Inc UNH reported on Tuesday upbeat earnings for its third quarter.
UnitedHealth Q3 Earnings Review: Deserved Sell-Off Is Not A 'Buy The Dip' Opportunity (Rating Downgrade)
UnitedHealth's Q3 earnings, released yesterday, revealed significant challenges, including rising healthcare costs and reduced rate increases, impacting profitability and leading to an 8% stock drop. Medicare Advantage headwinds and increased medical benefit ratios are squeezing margins, making the business less profitable than a year ago. The company has struggled with implementing value-based care, which was supposed to reduce costs but hasn't yet delivered the expected savings.
Brokers Suggest Investing in UnitedHealth (UNH): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
UnitedHealth Stock Plunges After Earnings, But It's A Buy Now
UnitedHealth Group's stock fell 8.1% despite beating Q3 estimates due to conservative 2024 and 2025 EPS guidance. However, I rate it as a Buy. The company's long-term EPS growth target of 13-16% is achievable, supported by the company's strong track record. UNH's current valuation is attractive, trading at a P/E ratio that aligns with historical trends, suggesting potential for double-digit annual returns based on expected EPS growth.
UnitedHealth is still a 'gold standard stock' after earnings drop: Cantor Fitzgerald's Sarah James
Sarah James, Cantor Fitzgerald, joins 'Fast Money' to talk how she is playing UnitedHealth's stock right now.
3-Stock Lunch: UnitedHealth, Johnson & Johnson & Wolfspeed
Jay Hatfield, Infra-Cap CEO, joins 'Power Lunch' to discuss stock plays for three stocks.
UnitedHealth Q3 Earnings Beat on Domestic Commercial Business
UNH's third-quarter earnings benefit on the back of client wins in the Optum Rx sub-unit, partly offset by an elevated operating expense level.
